NCT03764293 2024-02-06A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCJiangsu HengRui Medicine Co., Ltd.Phase 3 Completed543 enrolled 13 charts
NCT03396211 2023-04-07A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerElevar TherapeuticsPhase 1 Completed30 enrolled